Indication	Sponsor Protocol Number NCT Number	Study Description	Investigator 24 Hour Contact Info	Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)	Sponsor Emergency Contact If local contacts are unavailable
Combined COVID/Flu Vaccine	Moderna mRNA-1083-P301 NCT06097273	A Phase 3, Randomized, Observer-blind, Active-control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age	Brian Curtis, MD 541-754-1150	Lisa Buchheit Josh Borunda 541-766-2163	1-888-483-7729
Type 2 Diabetes	Eli Lilly I8F-MC-GPHE NCT05433584	A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes (SURPASS-EARLY)	Brian Curtis, MD 541-754-1150	Rich Tomasco Josh Borunda 541-766-2163	317-651-8478
Type 2 Diabetes	Eli Lilly J2A-MC-GZGU NCT06045221	A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Oral Semaglutide in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin (ACHIEVE-3)	Shannon Hopson, DO 541-754-1150	Rich Tomasco Josh Borunda 541-766-2163	765-418-0528
Type 2 Diabetes	Eli Lilly J2A-MC-GZGT NCT05971940	A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone (ACHIEVE-1)	Shannon Hopson, DO 541-754-1150	Erin Thompson Josh Borunda 541-766-2163	**317-997-5593**
Metabolic Outcomes in obese patients with cardiovascular disease (or risk of)	Eli Lilly SURMOUNT-MMO I8F-MC-GPIJ NCT05556512	Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity	Brian Curtis, MD 541-754-1150	Kim Tally Josh Borunda 541-766-2163	+34 91 6233535

Indication	**Sponsor Protocol Number** **NCT Number**	**Study Description**	**Investigator 24 Hour Contact Info**	**Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)**	**Sponsor Emergency Contact** **If local contacts are unavailable**
Severe Asthma	GSK 206785 NIMBLE NCT04718389	A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab	Roland Solensky, MD 541-754-1150	Lisa Buchheit Josh Borunda 541-766-2163	(484) 868 2102